Indicated as an adjunct to diet and exercise to improve glycemic control in patients 10 years and older with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.1
COVID-19 Notice: Novo Nordisk Information and Resources. Click here.
Victoza®—indicated to reduce the risk of major adverse CV events (CV death, non‑fatal myocardial infarction, or non‑fatal stroke) in adults with type 2 diabetes mellitus and established CV disease1
Victoza®—a once-daily GLP‑1 RA therapy
Looking for patient savings?

Considering once-daily Victoza® for T2D?
Consider prescribing once-weekly Ozempic® for your appropriate adult patients
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction or nonfatal stroke) in adults with type 2 diabetes mellitus and established CVD.2
Considering once-daily Victoza® for T2D?
Choose once-weekly Ozempic® (semaglutide) injection 0.5 mg or 1 mg for your appropriate adult patients
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction or nonfatal stroke) in adults with type 2 diabetes mellitus and established CVD.2
What could your patients who make the change to Ozempic® expect?
aData from VANTAGE Fingertip Formulary bridge/July 2019 Nomenclature, and Xponent PlanTrak using week ending 08/02/2019; only considers bridged volume; excludes cash and mail order data.
Ozempic® Important Safety Information
WARNING: RISK OF THYROID C-CELL TUMORS
- In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Ozempic® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.
- Ozempic® is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Ozempic® and inform them of symptoms of thyroid tumors (eg, a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Ozempic®.